Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Axitinib Adjuvant Therapy for High-Risk Non-Clear RCC
NCT05768464Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, axitinib in renal cell carcinoma (RCC), sponsored by Nanjing Drum-Tower Hospital. Started Feb 2023; status: recruiting.
02
Drugs
toripalimabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05768464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768464.